Sponsor

Centre Hospitalier Universitaire De Nantes

France 5 Allee De L Ile Gloriette, Cs 69301, 44093 Nantes, France

About the sponsor

Acute myeloid leukemia, acute leukemia, multiple myeloma, and mantle cell lymphoma are central areas of interest, alongside transplant-linked care for high-risk blood cancers. The portfolio also includes studies in minimal residual disease assessment and allogeneic stem cell transplantation.

Acute myeloid leukemia
Multiple myeloma
Mantle cell lymphoma
Allogeneic stem cell transplantation
Minimal residual disease

Research activity extends to immune-based and transplant-adjacent approaches in patients with relapsed, refractory, or high-risk hematological disease.

About Specializations

Centre Hospitalier Universitaire De Nantes runs clinical trials in conditions such as Plasma cell myeloma, Renal transplant, Pneumonia, Procedural pain, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

40 clinical trials

Cardiac amyloidosis

Recruiting

InvestigationalNo placebo

Evaluation of [68Ga]Ga-FAPI-46 PET Imaging for Staging and Detecting Disease Progression in Patients with Transthyretin Cardiac Amyloidosis

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Periarthritis

Recruiting

Registered drug

Lidocaine Hydrochloride, Sodium Chloride, and Betamethasone Injections for Adults with Adhesive Capsulitis: A Pilot Efficacy Study

Registered drug

France

Participants:18–64 years
Substances:Sodium Chloride
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Sickle cell disease

Recruiting

Registered drug

Study of lidocaine to reduce opioid use in patients with sickle cell disease experiencing severe pain crisis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Thrombocytopenia

Recruiting

Registered drug

Study of romiplostim given before heart surgery in patients with low platelet counts to improve blood clotting after surgery

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Romiplostim
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Cardiac operation

Recruiting

Registered drugNo placebo

Study of Clindamycin Use During Heart Surgery with Extracorporeal Circulation to Prevent Surgical Site Infections

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Clindamycin
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Craniocerebral injury

Recruiting

Registered drugNo placebo

Study of hypertonic saline solution and mannitol to improve recovery in patients with traumatic brain injury and high risk of intracranial hypertension

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Mannitol
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+1

Recruiting

Registered drugNo placebo

Study of Gallium (68Ga) edotreotide, Fluorocholine (18F) and Fludeoxyglucose (18F) PET imaging for detection and staging of liver cancer and gastro-entero-pancreatic tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fludeoxyglucose (18F)
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Endocarditis staphylococcal

Recruiting

Registered drugNo placebo

Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cefazolin Sodium
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Dysmenorrhoea

Recruiting

Registered drug

Evaluation of Botulinum Toxin Injections for Women with Severe Primary Dysmenorrhea Unresponsive to First-Line Treatments

Registered drug

France

Participants:18–64 years
Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
Sponsor:Centre Hospitalier Universitaire De Nantes